Ladenburg upgrades Zynex, says NiCO opportunity ‘should not be overlooked’

As previously reported, Ladenburg upgraded Zynex (ZYXI) to Buy from Neutral with a $3.70 price target While the firm recognizes disruptions in the pain segment are “material,” creating uncertainty and negatively impacting the company’s performance, it argues that the opportunity for the NiCO laser pulse oximeter “should not be overlooked,” citing the differentiated technology and agency-driven efforts to provide more equitable care.